Publication: IND240A and IND240B

An immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021)

Comparison of two distinct treatment modalities and identification of molecularly defined subgroups that would allow to individualize the choice of initial treatment. Each sub-study has a Simon’s 2-stage design. If no response is seen (H0: ORR ≤ 5%) in the first 10 patients a planned biomarker review will be conducted to determine if biomarker expression eligibility should be amended or if the sub-study should close.